Recombinant human erythropoietin - Max Planck Institute

Drug Profile

Recombinant human erythropoietin - Max Planck Institute

Latest Information Update: 26 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Max Planck Institute of Experimental Medicine
  • Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Multiple sclerosis; Schizophrenia

Most Recent Events

  • 21 Sep 2006 Stem Cell Therapeutics has entered into an Option to Acquire agreement for the erythropoietin based therapies for the treatment of multiple sclerosis and schizophrenia
  • 21 Sep 2006 Phase-II clinical trials in Multiple sclerosis in Germany (unspecified route)
  • 21 Sep 2006 Phase-II clinical trials in Schizophrenia in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top